Generated by AI
MiMedx Group, Inc. is a healthcare company focused on regenerative biologics and advanced wound care products. MiMedx Group, Inc. develops, manufactures, and markets placental tissue allografts and other biomaterial products used in wound care, surgical, burn, orthopedic, spine, sports medicine, ophthalmic, and dental applications. Its portfolio includes products derived from human placental and umbilical cord tissues, designed to support tissue repair and biologic healing in clinical settings. The company serves hospitals, physicians, and other healthcare providers through a range of wound management and surgical solutions. MiMedx Group, Inc. operates as a specialized player in the broader regenerative medicine market, with products that are used across multiple therapeutic areas where biologic tissue processing and advanced treatment options are important.
Website1775 West Oak Commons Court, NE
Marietta, GA, 30062
United States
The latest articles about MDXG.
MARIETTA, Ga., Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Canaccord MedTech, Diagnostics and Digital Health & Services Forum | New York, NYWednesday, November 11, 20261:1 sessions + presentation (9:00 am EST): webcast Craig-Hallum 17th Annual Alpha Select Conference | New York, NYTuesday, November 17, 20261:1 sessions Investors interes
Summary of Oct 29's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Summary of Jun 20's posts. Generated by AI.
Summary of Sep 13's posts. Generated by AI.
Investors talking about MDXG also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.